tiprankstipranks
Advertisement
Advertisement

RANI Stock Latest News

Rani Therapeutics reports initial data from RT-114 study
The FlyRani Therapeutics reports initial data from RT-114 study
6d ago
RANI
Rani Therapeutics Maintained at Buy as Partnerships Highlight Underappreciated Pipeline; $11 Price Target Reaffirmed
PremiumRatings
Rani Therapeutics Maintained at Buy as Partnerships Highlight Underappreciated Pipeline; $11 Price Target Reaffirmed
8d ago
RANI
Rani Therapeutics announces research, development collaboration with PegBio
PremiumThe Fly
Rani Therapeutics announces research, development collaboration with PegBio
11d ago
RANI
Rani Therapeutics management to meet virtually with Lake Street
PremiumThe Fly
Rani Therapeutics management to meet virtually with Lake Street
19d ago
RANI
Rani Therapeutics Appoints New Chief Financial Officer
PremiumCompany Announcements
Rani Therapeutics Appoints New Chief Financial Officer
21d ago
8K
RANI
Rani Therapeutics appoints Nicholas Maestas as CFO
PremiumThe FlyRani Therapeutics appoints Nicholas Maestas as CFO
22d ago
RANI
TPST
Rani Therapeutics Rated Buy as Analyst Highlights RT-114 Progress, Chugai Partnership and Cash Runway; $11 Price Target Reiterated
Premium
Ratings
Rani Therapeutics Rated Buy as Analyst Highlights RT-114 Progress, Chugai Partnership and Cash Runway; $11 Price Target Reiterated
2M ago
RANI
Rani Therapeutics Shareholders Back Board and Auditor at Meeting
Premium
Company Announcements
Rani Therapeutics Shareholders Back Board and Auditor at Meeting
2M ago
8K
RANI
Rani Therapeutics Announces $20 Million Equity Financing
PremiumCompany Announcements
Rani Therapeutics Announces $20 Million Equity Financing
2M ago
8K
RANI
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price
PremiumCompany Announcements
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price
2M ago
RANI
Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice
PremiumCompany Announcements
Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice
2M ago
8K
RANI
Rani Therapeutics CFO Svai Sanford to step down
PremiumThe Fly
Rani Therapeutics CFO Svai Sanford to step down
2M ago
RANI
Rani Therapeutics reports Q1 EPS (4c), consensus (5c)
PremiumThe FlyRani Therapeutics reports Q1 EPS (4c), consensus (5c)
2M ago
RANI
Edward Nash Reiterates Buy on Rani Therapeutics, Maintains Unchanged $5 Price Target Amid Encouraging RT-114 and Oral Biologics Platform Outlook
Premium
Ratings
Edward Nash Reiterates Buy on Rani Therapeutics, Maintains Unchanged $5 Price Target Amid Encouraging RT-114 and Oral Biologics Platform Outlook
2M ago
RANI
Rani Therapeutics price target lowered to $5 from $9 at Canaccord
Premium
The Fly
Rani Therapeutics price target lowered to $5 from $9 at Canaccord
4M ago
RANI
Rani Therapeutics reports Q4 EPS (7c), consensus (7c)
PremiumThe Fly
Rani Therapeutics reports Q4 EPS (7c), consensus (7c)
4M ago
RANI
Rani Therapeutics Holdings options imply 17.3% move in share price post-earnings
PremiumThe Fly
Rani Therapeutics Holdings options imply 17.3% move in share price post-earnings
4M ago
RANI
RANI Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
RANI Upcoming Earnings Report: What to Expect?
4M ago
RANI
Rani Therapeutics promotes Javadi to Chief Technical Officer
PremiumThe Fly
Rani Therapeutics promotes Javadi to Chief Technical Officer
6M ago
RANI
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
6M ago
IBN
LQD
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
6M ago
BARK
CBRL
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
6M ago
RR
ENB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >